This video presents the myeloma treatment algorithm 2025 for transplant-ineligible patients, shared by Dr. Vincent Rajkumar at ASCO 2025. Designed for oncology professionals on ASCO.org and OncologyTube.com, it explains treatment strategies for varied patient needs.
What the Video Covers
- Stratifying patients into ideal, frail, or access-limited categories.
- Selecting initial regimens, such as Dara-VRd or VRd, based on patient profiles.
- Assessing risk to identify standard versus high-risk myeloma cases.
- Planning long-term maintenance therapy for different patient groups.
Why This Algorithm Is Relevant
A 2024 NCI trial showed Dara-VRd reduced progression risk by 60% compared to VRd alone, with 84% of Dara-VRd patients progression-free after 4 years versus 68% for VRd. This algorithm incorporates such data to guide oncologists. It also considers practical issues, like treatment access, making it applicable in diverse clinical settings. For hematologists, researchers, and clinicians, the myeloma treatment algorithm 2025 provides a structured approach to patient care.
Key Steps for Oncology Professionals
The video outlines steps to apply the algorithm in practice:
- Assess: Categorize patients to guide therapy decisions.
- Select: Choose regimens like Dara-VRd for ideal patients or VRd for access-limited cases.
- Stratify: Evaluate risk to inform maintenance plans.
- Plan: Focus on long-term outcomes with tailored care.
Connect with the Oncology Community
Share your feedback on this myeloma treatment algorithm 2025 in the comments. For more resources, visit ASCO.org and OncologyTube.com. Use #ASCO25 to join discussions with colleagues.
Explore More Oncology Videos